Clinical Trial News and Research

RSS

Study: Stem cells from pelvic bone marrow may help hearts beat stronger

Stem cells from the pelvic bone may help hearts beat stronger. Doctors and other clinicians at the Orlando Health Heart Institute are researching the use of stem cells from pelvic bone marrow to restore tissue and improve heart function after muscle damage from heart attacks.

12 Apr 2012

Mayo Clinic to offer novel device for patients with GERD

Mayo Clinic in Florida will be one of the first health care institutions in the United States to offer a newly approved device to treat gastroesophageal reflux disease (GERD). The condition, also known as acid reflux disease, can lead to serious health problems.

12 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

Lung cancer screening could be cost effective: Study finds

A new study shows that screening longtime tobacco users for lung cancer would be less costly than the widely accepted practice of screening for breast, cervical and colorectal cancers and would reduce the death toll of lung cancer by an estimated 15,000 lives a year.

11 Apr 2012

Intact Vascular’s Tack-it Endovascular Stapler device receives CE Mark approval

Intact Vascular, a medical device company and developer of products for minimally invasive peripheral vascular procedures, today announced its European notified body has granted the company ISO Certification and CE Mark approval for Tack-it Endovascular Stapler device.

11 Apr 2012

Omeros initiates enrollment in second Phase 3 trial of OMS302

Omeros Corporation today announced that patient enrollment has begun in the Company's second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

10 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

UCSD surgeon implants new INX device in a 29-year old patient with GERD

On Monday, April 9, Santiago Horgan, MD, chief of minimally invasive surgery at UC San Diego Health System implanted the new FDA-approved LINX device in a 29-year old patient suffering from gastroesophageal reflux disease (GERD), a chronic digestive disease that can lead to severe inflammation, stricture, Barrett's esophagus and esophageal cancer.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

9 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

'Benefits and burdens' of participating in clinical research trials

In one of the first studies of its kind, University of Pennsylvania School of Nursing researchers have identified what cancer patients consider the "benefits and burdens" of participating in clinical research trials.

7 Apr 2012

FDA grants IDE approval for Arteriocyte's Magellan MAR01 Phase I Compartment Syndrome clinical trial

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.

7 Apr 2012

Presage Biosciences enters cancer research agreement with Millennium

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.

7 Apr 2012

Hot topics in the Journal of Bone and Joint Surgery

Airport security screening has increased substantially during the past decade, while joint replacement procedures also continue to rise. According to the American Academy of Orthopaedic Surgeons (AAOS), in 2009, nearly 300,000 total hip replacements (THR) were performed in the United States.

6 Apr 2012

Innate patient factors, overall morbidity affect neurodevelopment in infants with single-ventricle disease

In the largest multicenter clinical trial of children undergoing early-stage surgery for single-ventricle heart defects, differences in intraoperative management did not significantly affect neurodevelopmental outcomes at 14 months of age. Instead, the strongest influences were innate patient characteristics and general medical morbidity during the child's first year of life.

6 Apr 2012

Methylphenidate may help induce recovery from propofol anesthesia

The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol. Members of the same Massachusetts General Hospital (MGH) research team that reported the isoflurane study are publishing similar results for propofol in the May issue of Anesthesiology, and their paper has been issued online.

6 Apr 2012

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Key data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical trial programme, HCVerso, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities.

6 Apr 2012